Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 313.00 | |
5 mg | In stock | $ 690.00 | |
10 mg | In stock | $ 992.00 | |
25 mg | In stock | $ 1,470.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,680.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 981.00 |
Description | Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) is an oral dual inhibitor of Bcl-2 and Bcl-xl, with IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. Lisaftoclax is used to treat chronic lymphocytic leukemia (CLL) by inhibiting the action of the BCL-2 protein, which promotes the death of leukemia cells. |
Targets&IC50 | BCL-XL:5.9 nM, BCL2:2 nM |
In vitro | Lisaftoclax shows IC50s of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4 11 cells and Bcl-xl dependent Molm 13 cells[1]. |
Synonyms | Bcl-2/Bcl-xl inhibitor 1, APG-2575 |
Molecular Weight | 882.42 |
Formula | C45H48ClN7O8S |
CAS No. | 2180923-05-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 225 mg/mL (255 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lisaftoclax 2180923-05-9 Apoptosis BCL APG2575 APG 2575 Bcl-2/Bcl-xl inhibitor 1 APG-2575 inhibitor inhibit